Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Calithera Biosciences (CALA) announced the granting of non-qualified stock options to three new employees, totaling 138,500 shares at an exercise price of $3.54. The options will vest over time, with one-fourth vesting after a year and the remainder in thirty-six monthly installments. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and is part of Calithera's 2018 Inducement Plan. The company is focused on developing novel therapies for cancer treatment. Future statements regarding progress and safety of product candidates are subject to risks, impacting stock performance.

Positive

• Grant of stock options may attract and retain talent.
• Vesting schedule aligns employee interests with company performance.

Negative

• Stock options may dilute existing shareholders' equity.
• Clinical trials may not yield expected results, affecting future stock value.

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the compensation committee of the company’s board of directors granted three new employees non-qualified stock options to purchase an aggregate of 138,500 shares of Calithera’s common stock, at a per share exercise price of $3.54, the closing trading price on October 30, 2020. One-fourth of the options vest one year after the respective vesting commencement dates, and the balance of the options vest in a series of thirty-six successive equal monthly installments thereafter and was granted pursuant to the Calithera Biosciences, Inc. 2018 Inducement Plan, or Inducement Plan, which was approved by Calithera’s board of directors in January 2018 in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options also have a ten year term and are subject to the terms and conditions of the Inducement Plan and the stock option agreement pursuant to which the options were granted.

The stocks options were granted as an inducement material to the new employees entering into employment with Calithera in accordance with Nasdaq Listing Rule 5635(c)(4).

About Calithera

Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the safety, tolerability and efficacy of Calithera’s product candidates, the overall advancement of Calithera’s product candidates in clinical trials, the unmet need in the treatment of patients with advanced disease, and Calithera’s plans to continue development of its product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, and other periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

SOURCE: Calithera Biosciences, Inc.

CONTACT:

Jennifer McNealey
ir@Calithera.com
650-870-1071

FAQ

What stock options were granted by Calithera Biosciences on November 2, 2020?

Calithera granted non-qualified stock options to three new employees for a total of 138,500 shares at an exercise price of $3.54.

How do the stock options for Calithera employees vest?

One-fourth of the options vest one year after the vesting commencement date, and the remaining options vest in thirty-six equal monthly installments.

What is the significance of Nasdaq Listing Rule 5635(c)(4) in Calithera's stock option grant?

This rule allows the granting of stock options as an inducement for new employees.

What risks are associated with Calithera's forward-looking statements?

Risks include the uncertainty of clinical trial outcomes and the possibility of not receiving required regulatory approvals.